Harveshp Mogal, MD, MS, FACS, DABS, FSSO
Dr. Harveshp Mogal is a surgical oncologist at UW Medicine and the Fred Hutchinson Cancer Center in Seattle, Washington. Dr. Mogal’s medical specialties include gastrointestinal cancer, soft tissue tumors, liver tumors, and skin cancer care, as well as treatment of malignant peritoneal mesothelioma.
Dr. Mogal is a board-certified surgical oncologist whose focus on the care of patients with advanced cancers of the abdomen has led to his expertise in the complex combination treatment called cytoreductive surgery with hyperthermic intraperitoneal mesothelioma, or CRS with HIPEC. He is dedicated to working with a multidisciplinary team to deliver evidence-based cancer care.[1]
Education and Career
Dr. Mogal has an extensive educational background, starting with earning his medical degree at D Y Patil University and the University of Mumbai. He began his General Surgical Residency at Grant Medical College, then moved on to the University of Medical Center before pursuing an additional internship and residency in General Surgery at St. Louis University School of Medicine. He completed a fellowship at Wake Forest University, where he developed expertise in hyperthermic intraperitoneal chemotherapy, a protocol used to treat abdominal cancers that have spread to the lining of the abdominal cavity, as well as malignant peritoneal mesothelioma. He also earned a Master of Science in Clinical and Translational Science at the Medical College of Wisconsin.[1]
Today he is an Associate Professor in the Department of Surgery at the UW School of Medicine and also serves as the director of regional cancer therapies at UW Medicine.
Professional Memberships
Dr. Mogal is a member of several professional medical organizations, including:[2]
American College of Surgeons
Society of Surgical Oncology
American Medical Association
Association for Academic Surgery
Milwaukee Academy of Surgery
Milwaukee GI Society
Research
Dr. Mogal’s clinical research focuses on the outcomes of patients who undergo surgical treatment for peritoneal malignancies and sarcomas.
His recent publications include:[2]
- Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. Bonny Chau, Elizabeth T Loggers, Lee D Cranmer, Harveshp Mogal, Jeremy M Sharib, Edward Y Kim, Stephanie K Schaub, Kelly G Paulson, Hannah M Linden, Jennifer M Specht,…>; American Journal of Clinical Oncology. 2023 Dec 1
- Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. Robert S Krouse, Garnet L Anderson, Kathryn B Arnold, Cynthia A Thomson, Valentine N Nfonsam, Mazin F Al-Kasspooles, Joan L Walker, Virginia Sun, Angeles Alvarez Secor…>; The Lancet. Gastroenterology & Hepatology. 2023 Oct 1
- ASO Visual Abstract: Validation of the AJCC 8th Edition Staging System for Disseminated Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Gopika SenthilKumar, Anai N Kothari, Ugwuji N Maduekwe, Keith Fournier, Daniel E Abbott, Gregory C Wilson, Sameer H Patel, Jonathan Greer, Fabian Johnston, Sean P Dine…>; Annals of Surgical Oncology. 2023 Sep 1
